We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+33.14%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$7.1B
AUM Growth
+$1.15B
Cap. Flow
-$108M
Cap. Flow %
-1.52%
Top 10 Hldgs %
31.14%
Holding
166
New
24
Increased
29
Reduced
28
Closed
31

Top Buys

Rank Stock Value
1
BNR
Burning Rock Biotech
BNR
+$130M
2
RPTX
Repare Therapeutics
RPTX
+$110M
3
ORIC icon
Oric Pharmaceuticals
ORIC
+$93.3M
4
BIIB icon
Biogen
BIIB
+$70.8M
5
TBPH icon
Theravance Biopharma
TBPH
+$60.2M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$237M
2
PFE icon
Pfizer
PFE
+$98.3M
3
GILD icon
Gilead Sciences
GILD
+$98M
4
ALEC icon
Alector
ALEC
+$64.9M
5
HCA icon
HCA Healthcare
HCA
+$63.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.96%
2 Financials 1.61%
3 Miscellaneous 0.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RGNX icon
151
Regenxbio
RGNX
$518M
– –
-267,700
Closed -$8.67M
RVMD icon
152
Revolution Medicines
RVMD
$43.6B
– –
-300,000
Closed -$6.57M
FLNA
153
CALL
Filana Therapeutics
FLNA
$33.2M
– –
-250,000
Closed -$1.53M
SPY icon
154
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$799B
– –
-50,000
Closed -$15.8M
STRO icon
155
Sutro Biopharma
STRO
$272M
– –
-10,480
Closed -$1.07M
SYK icon
156
Stryker
SYK
$108B
– –
-371,100
Closed -$61.8M
XBI icon
157
State Street SPDR S&P Biotech ETF
XBI
$10.3B
– –
-127,200
Closed -$9.85M
XLV icon
158
State Street Health Care Select Sector SPDR ETF
XLV
$43.5B
– –
-113,200
Closed -$10M
ZLAB icon
159
Zai Lab
ZLAB
$2.8B
– –
-254,000
Closed -$13.1M
TVRD
160
Tvardi Therapeutics
TVRD
$23.5M
– –
-16,467
Closed -$7.83M
NBSE
161
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
– –
-18,556
Closed -$2.64M
APTX
162
DELISTED
Aptinyx Inc. Common Stock
APTX
– –
-1,162,108
Closed -$2.51M
AGRX
163
DELISTED
Agile Therapeutics
AGRX
– –
-600
Closed -$2.23M
OTIC
164
DELISTED
Otonomy, Inc.
OTIC
– –
-71,994
Closed -$142K
XENT
165
DELISTED
Intersect ENT, Inc
XENT
– –
-68,553
Closed -$812K
PFNX
166
DELISTED
Pfenex Inc.
PFNX
– –
-1,305,034
Closed -$11.5M
3 4 5 6
7

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2020 Portfolio in Review

As of Q2 2020, OrbiMed held 166 positions worth $7.1B, up 19% from $5.95B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

OrbiMed's Q2 2020 filing shows 24 new, 29 increased, 28 reduced and 31 closed positions. Its largest new stake was Burning Rock Biotech: 474,607 shares worth $128M. The largest sale was Ascendis Pharma A/S, an estimated $237M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Financials and Miscellaneous.

  • OrbiMed's largest Q2 2020 buy was Burning Rock Biotech: 474,607 shares worth $128M.
  • OrbiMed added most to Biogen in Q2 2020, an estimated $70.8M increase.
  • OrbiMed's biggest Q2 2020 reduction was Ascendis Pharma A/S, cutting an estimated $237M.
  • OrbiMed fully exited Pfizer in Q2 2020, selling an estimated $98.3M.
  • OrbiMed's ten largest holdings make up 31% of its $7.1B portfolio in Q2 2020.
  • OrbiMed opened 24 new positions and closed 31 in Q2 2020.
  • OrbiMed's portfolio value rose 19% quarter-over-quarter to $7.1B.

Based on OrbiMed's 13F filing for Q2 2020, filed 14 Aug 2020.